Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan
Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years,...
Gespeichert in:
| Veröffentlicht in: | International journal of rheumatic diseases 2018-04, Vol.21 (4), p.772-787 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 787 |
|---|---|
| container_issue | 4 |
| container_start_page | 772 |
| container_title | International journal of rheumatic diseases |
| container_volume | 21 |
| creator | Yu, Kuang‐Hui Chen, Der‐Yuan Chen, Jiunn‐Horng Chen, Shih‐Yang Chen, Shyh‐Ming Cheng, Tien‐Tsai Hsieh, Song‐Chou Hsieh, Tsu‐Yi Hsu, Pai‐Feng Kuo, Chang‐Fu Kuo, Mei‐Chuan Lam, Hing‐Chung Lee, I‐Te Liang, Toong‐Hua Lin, Hsiao‐Yi Lin, Shih‐Chang Tsai, Wen‐Pin Tsay, Gregory J. Wei, James Cheng‐Chung Yang, Chung‐Han Tsai, Wen‐Chan |
| description | Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long‐term urate‐lowering treatment. Urate‐lowering drugs should be used during the inter‐critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate‐lowering therapy should aim to maintain serum uric acid (sUA) level |
| doi_str_mv | 10.1111/1756-185X.13266 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1990857662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2020659863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4846-f4071bdf373f80c3ac9bca0c3714e54c89f74c02176ad7396d590d89f1eeaf8b3</originalsourceid><addsrcrecordid>eNqFkD1PwzAQhi0EolCY2VAkFpa0dpzYCVtV8SVawVAkNstx7OIqcYodq-q_xyWlAwu3-HR67tX5AeAKwREKNUY0IzHKs48RwgkhR-DsMDk-9CkagHPnVhAShAk9BYOkwCTwyRl4mXPDl7KRpotaFS1b30XcVNHndi2tt1rIRvO7aO7rTlfaCb2uteF2G4nWOGmcd5E20YLrDTcX4ETx2snL_TsE7w_3i-lTPHt9fJ5OZrFI85TEKoUUlZXCFKscCsxFUQoeGopSmaUiLxRNBUwQJbyiuCBVVsAqTJGUXOUlHoLbPndt2y8vXceacJmsa25k6x1DRQHzjBKSBPTmD7pqvTXhOpbABJKsyAkO1LinhG2ds1KxtdVN-CVDkO08s51JtrPKfjyHjet9ri8bWR34X7EByHpgo2u5_S-PTd5mffA3ICaHdQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2020659863</pqid></control><display><type>article</type><title>Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yu, Kuang‐Hui ; Chen, Der‐Yuan ; Chen, Jiunn‐Horng ; Chen, Shih‐Yang ; Chen, Shyh‐Ming ; Cheng, Tien‐Tsai ; Hsieh, Song‐Chou ; Hsieh, Tsu‐Yi ; Hsu, Pai‐Feng ; Kuo, Chang‐Fu ; Kuo, Mei‐Chuan ; Lam, Hing‐Chung ; Lee, I‐Te ; Liang, Toong‐Hua ; Lin, Hsiao‐Yi ; Lin, Shih‐Chang ; Tsai, Wen‐Pin ; Tsay, Gregory J. ; Wei, James Cheng‐Chung ; Yang, Chung‐Han ; Tsai, Wen‐Chan</creator><creatorcontrib>Yu, Kuang‐Hui ; Chen, Der‐Yuan ; Chen, Jiunn‐Horng ; Chen, Shih‐Yang ; Chen, Shyh‐Ming ; Cheng, Tien‐Tsai ; Hsieh, Song‐Chou ; Hsieh, Tsu‐Yi ; Hsu, Pai‐Feng ; Kuo, Chang‐Fu ; Kuo, Mei‐Chuan ; Lam, Hing‐Chung ; Lee, I‐Te ; Liang, Toong‐Hua ; Lin, Hsiao‐Yi ; Lin, Shih‐Chang ; Tsai, Wen‐Pin ; Tsay, Gregory J. ; Wei, James Cheng‐Chung ; Yang, Chung‐Han ; Tsai, Wen‐Chan</creatorcontrib><description>Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long‐term urate‐lowering treatment. Urate‐lowering drugs should be used during the inter‐critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate‐lowering therapy should aim to maintain serum uric acid (sUA) level <6.0 mg/dL. For patients with tophi, the initial goal can be set at lowering sUA to <5.0 mg/dL to promote tophi dissolution. The goal of this consensus paper was to improve gout and hyperuricemia management at a more comprehensive level. The content of this consensus paper was developed based on local epidemiology and current clinical practice, as well as consensuses from two multidisciplinary meetings and recommendations from Taiwan Guideline for the Management of Gout and Hyperuricemia.</description><identifier>ISSN: 1756-1841</identifier><identifier>EISSN: 1756-185X</identifier><identifier>DOI: 10.1111/1756-185X.13266</identifier><identifier>PMID: 29363262</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Arthritis ; Cardiovascular diseases ; Cartilage ; Crystals ; Diabetes mellitus ; Gout ; Hyperuricemia ; Joint diseases ; Lithiasis ; Management ; Metabolic syndrome ; Patients ; Psoriasis ; Rheumatism ; Soft tissues ; Tendons ; Thyroid ; urate‐lowering agents ; Uric acid</subject><ispartof>International journal of rheumatic diseases, 2018-04, Vol.21 (4), p.772-787</ispartof><rights>2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</rights><rights>2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.</rights><rights>International Journal of Rheumatic Diseases © 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4846-f4071bdf373f80c3ac9bca0c3714e54c89f74c02176ad7396d590d89f1eeaf8b3</citedby><cites>FETCH-LOGICAL-c4846-f4071bdf373f80c3ac9bca0c3714e54c89f74c02176ad7396d590d89f1eeaf8b3</cites><orcidid>0000-0001-6251-0231</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2F1756-185X.13266$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2F1756-185X.13266$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29363262$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yu, Kuang‐Hui</creatorcontrib><creatorcontrib>Chen, Der‐Yuan</creatorcontrib><creatorcontrib>Chen, Jiunn‐Horng</creatorcontrib><creatorcontrib>Chen, Shih‐Yang</creatorcontrib><creatorcontrib>Chen, Shyh‐Ming</creatorcontrib><creatorcontrib>Cheng, Tien‐Tsai</creatorcontrib><creatorcontrib>Hsieh, Song‐Chou</creatorcontrib><creatorcontrib>Hsieh, Tsu‐Yi</creatorcontrib><creatorcontrib>Hsu, Pai‐Feng</creatorcontrib><creatorcontrib>Kuo, Chang‐Fu</creatorcontrib><creatorcontrib>Kuo, Mei‐Chuan</creatorcontrib><creatorcontrib>Lam, Hing‐Chung</creatorcontrib><creatorcontrib>Lee, I‐Te</creatorcontrib><creatorcontrib>Liang, Toong‐Hua</creatorcontrib><creatorcontrib>Lin, Hsiao‐Yi</creatorcontrib><creatorcontrib>Lin, Shih‐Chang</creatorcontrib><creatorcontrib>Tsai, Wen‐Pin</creatorcontrib><creatorcontrib>Tsay, Gregory J.</creatorcontrib><creatorcontrib>Wei, James Cheng‐Chung</creatorcontrib><creatorcontrib>Yang, Chung‐Han</creatorcontrib><creatorcontrib>Tsai, Wen‐Chan</creatorcontrib><title>Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan</title><title>International journal of rheumatic diseases</title><addtitle>Int J Rheum Dis</addtitle><description>Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long‐term urate‐lowering treatment. Urate‐lowering drugs should be used during the inter‐critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate‐lowering therapy should aim to maintain serum uric acid (sUA) level <6.0 mg/dL. For patients with tophi, the initial goal can be set at lowering sUA to <5.0 mg/dL to promote tophi dissolution. The goal of this consensus paper was to improve gout and hyperuricemia management at a more comprehensive level. The content of this consensus paper was developed based on local epidemiology and current clinical practice, as well as consensuses from two multidisciplinary meetings and recommendations from Taiwan Guideline for the Management of Gout and Hyperuricemia.</description><subject>Arthritis</subject><subject>Cardiovascular diseases</subject><subject>Cartilage</subject><subject>Crystals</subject><subject>Diabetes mellitus</subject><subject>Gout</subject><subject>Hyperuricemia</subject><subject>Joint diseases</subject><subject>Lithiasis</subject><subject>Management</subject><subject>Metabolic syndrome</subject><subject>Patients</subject><subject>Psoriasis</subject><subject>Rheumatism</subject><subject>Soft tissues</subject><subject>Tendons</subject><subject>Thyroid</subject><subject>urate‐lowering agents</subject><subject>Uric acid</subject><issn>1756-1841</issn><issn>1756-185X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNqFkD1PwzAQhi0EolCY2VAkFpa0dpzYCVtV8SVawVAkNstx7OIqcYodq-q_xyWlAwu3-HR67tX5AeAKwREKNUY0IzHKs48RwgkhR-DsMDk-9CkagHPnVhAShAk9BYOkwCTwyRl4mXPDl7KRpotaFS1b30XcVNHndi2tt1rIRvO7aO7rTlfaCb2uteF2G4nWOGmcd5E20YLrDTcX4ETx2snL_TsE7w_3i-lTPHt9fJ5OZrFI85TEKoUUlZXCFKscCsxFUQoeGopSmaUiLxRNBUwQJbyiuCBVVsAqTJGUXOUlHoLbPndt2y8vXceacJmsa25k6x1DRQHzjBKSBPTmD7pqvTXhOpbABJKsyAkO1LinhG2ds1KxtdVN-CVDkO08s51JtrPKfjyHjet9ri8bWR34X7EByHpgo2u5_S-PTd5mffA3ICaHdQ</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Yu, Kuang‐Hui</creator><creator>Chen, Der‐Yuan</creator><creator>Chen, Jiunn‐Horng</creator><creator>Chen, Shih‐Yang</creator><creator>Chen, Shyh‐Ming</creator><creator>Cheng, Tien‐Tsai</creator><creator>Hsieh, Song‐Chou</creator><creator>Hsieh, Tsu‐Yi</creator><creator>Hsu, Pai‐Feng</creator><creator>Kuo, Chang‐Fu</creator><creator>Kuo, Mei‐Chuan</creator><creator>Lam, Hing‐Chung</creator><creator>Lee, I‐Te</creator><creator>Liang, Toong‐Hua</creator><creator>Lin, Hsiao‐Yi</creator><creator>Lin, Shih‐Chang</creator><creator>Tsai, Wen‐Pin</creator><creator>Tsay, Gregory J.</creator><creator>Wei, James Cheng‐Chung</creator><creator>Yang, Chung‐Han</creator><creator>Tsai, Wen‐Chan</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6251-0231</orcidid></search><sort><creationdate>201804</creationdate><title>Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan</title><author>Yu, Kuang‐Hui ; Chen, Der‐Yuan ; Chen, Jiunn‐Horng ; Chen, Shih‐Yang ; Chen, Shyh‐Ming ; Cheng, Tien‐Tsai ; Hsieh, Song‐Chou ; Hsieh, Tsu‐Yi ; Hsu, Pai‐Feng ; Kuo, Chang‐Fu ; Kuo, Mei‐Chuan ; Lam, Hing‐Chung ; Lee, I‐Te ; Liang, Toong‐Hua ; Lin, Hsiao‐Yi ; Lin, Shih‐Chang ; Tsai, Wen‐Pin ; Tsay, Gregory J. ; Wei, James Cheng‐Chung ; Yang, Chung‐Han ; Tsai, Wen‐Chan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4846-f4071bdf373f80c3ac9bca0c3714e54c89f74c02176ad7396d590d89f1eeaf8b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Arthritis</topic><topic>Cardiovascular diseases</topic><topic>Cartilage</topic><topic>Crystals</topic><topic>Diabetes mellitus</topic><topic>Gout</topic><topic>Hyperuricemia</topic><topic>Joint diseases</topic><topic>Lithiasis</topic><topic>Management</topic><topic>Metabolic syndrome</topic><topic>Patients</topic><topic>Psoriasis</topic><topic>Rheumatism</topic><topic>Soft tissues</topic><topic>Tendons</topic><topic>Thyroid</topic><topic>urate‐lowering agents</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yu, Kuang‐Hui</creatorcontrib><creatorcontrib>Chen, Der‐Yuan</creatorcontrib><creatorcontrib>Chen, Jiunn‐Horng</creatorcontrib><creatorcontrib>Chen, Shih‐Yang</creatorcontrib><creatorcontrib>Chen, Shyh‐Ming</creatorcontrib><creatorcontrib>Cheng, Tien‐Tsai</creatorcontrib><creatorcontrib>Hsieh, Song‐Chou</creatorcontrib><creatorcontrib>Hsieh, Tsu‐Yi</creatorcontrib><creatorcontrib>Hsu, Pai‐Feng</creatorcontrib><creatorcontrib>Kuo, Chang‐Fu</creatorcontrib><creatorcontrib>Kuo, Mei‐Chuan</creatorcontrib><creatorcontrib>Lam, Hing‐Chung</creatorcontrib><creatorcontrib>Lee, I‐Te</creatorcontrib><creatorcontrib>Liang, Toong‐Hua</creatorcontrib><creatorcontrib>Lin, Hsiao‐Yi</creatorcontrib><creatorcontrib>Lin, Shih‐Chang</creatorcontrib><creatorcontrib>Tsai, Wen‐Pin</creatorcontrib><creatorcontrib>Tsay, Gregory J.</creatorcontrib><creatorcontrib>Wei, James Cheng‐Chung</creatorcontrib><creatorcontrib>Yang, Chung‐Han</creatorcontrib><creatorcontrib>Tsai, Wen‐Chan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yu, Kuang‐Hui</au><au>Chen, Der‐Yuan</au><au>Chen, Jiunn‐Horng</au><au>Chen, Shih‐Yang</au><au>Chen, Shyh‐Ming</au><au>Cheng, Tien‐Tsai</au><au>Hsieh, Song‐Chou</au><au>Hsieh, Tsu‐Yi</au><au>Hsu, Pai‐Feng</au><au>Kuo, Chang‐Fu</au><au>Kuo, Mei‐Chuan</au><au>Lam, Hing‐Chung</au><au>Lee, I‐Te</au><au>Liang, Toong‐Hua</au><au>Lin, Hsiao‐Yi</au><au>Lin, Shih‐Chang</au><au>Tsai, Wen‐Pin</au><au>Tsay, Gregory J.</au><au>Wei, James Cheng‐Chung</au><au>Yang, Chung‐Han</au><au>Tsai, Wen‐Chan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan</atitle><jtitle>International journal of rheumatic diseases</jtitle><addtitle>Int J Rheum Dis</addtitle><date>2018-04</date><risdate>2018</risdate><volume>21</volume><issue>4</issue><spage>772</spage><epage>787</epage><pages>772-787</pages><issn>1756-1841</issn><eissn>1756-185X</eissn><abstract>Gout is an inflammatory disease manifested by the deposition of monosodium urate (MSU) crystals in joints, cartilage, synovial bursa, tendons or soft tissues. Gout is not a new disease, which was first documented nearly 5,000 years ago. The prevalence of gout has increased globally in recent years, imposing great disease burden worldwide. Moreover, gout or hyperuricemia is clearly associated with a variety of comorbidities, including cardiovascular diseases, chronic kidney disease, urolithiasis, metabolic syndrome, diabetes mellitus, thyroid dysfunction, and psoriasis. To prevent acute arthritis attacks and complications, earlier use of pharmacotherapeutic treatment should be considered, and patients with hyperuricemia and previous episodes of acute gouty arthritis should receive long‐term urate‐lowering treatment. Urate‐lowering drugs should be used during the inter‐critical and chronic stages to prevent recurrent gout attacks, which may elicit gradual resolution of tophi. The goal of urate‐lowering therapy should aim to maintain serum uric acid (sUA) level <6.0 mg/dL. For patients with tophi, the initial goal can be set at lowering sUA to <5.0 mg/dL to promote tophi dissolution. The goal of this consensus paper was to improve gout and hyperuricemia management at a more comprehensive level. The content of this consensus paper was developed based on local epidemiology and current clinical practice, as well as consensuses from two multidisciplinary meetings and recommendations from Taiwan Guideline for the Management of Gout and Hyperuricemia.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29363262</pmid><doi>10.1111/1756-185X.13266</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-6251-0231</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-1841 |
| ispartof | International journal of rheumatic diseases, 2018-04, Vol.21 (4), p.772-787 |
| issn | 1756-1841 1756-185X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1990857662 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Arthritis Cardiovascular diseases Cartilage Crystals Diabetes mellitus Gout Hyperuricemia Joint diseases Lithiasis Management Metabolic syndrome Patients Psoriasis Rheumatism Soft tissues Tendons Thyroid urate‐lowering agents Uric acid |
| title | Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T20%3A47%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20gout%20and%20hyperuricemia:%20Multidisciplinary%20consensus%20in%20Taiwan&rft.jtitle=International%20journal%20of%20rheumatic%20diseases&rft.au=Yu,%20Kuang%E2%80%90Hui&rft.date=2018-04&rft.volume=21&rft.issue=4&rft.spage=772&rft.epage=787&rft.pages=772-787&rft.issn=1756-1841&rft.eissn=1756-185X&rft_id=info:doi/10.1111/1756-185X.13266&rft_dat=%3Cproquest_cross%3E2020659863%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2020659863&rft_id=info:pmid/29363262&rfr_iscdi=true |